Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.70 |
| ▸ | MAPT | P10636 | 11/20 | 0.67 |
| ▸ | HPGD | P15428 | 8/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361734 | 0.94 | FDPS (0.66) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL686103 | 0.93 | FDPS (0.81) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL29085530 | 0.90 | FDPS (0.81) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL16067479 | 0.89 | FDPS (0.74) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL6963840 | 0.88 | FDPS (0.79) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL6372990 | 0.87 | FDPS (0.82) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL8907835 | 0.87 | FDPS (0.77) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL10417162 | 0.87 | FDPS (0.77) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL8310250 | 0.87 | FDPS (0.77) | FDPSALDH1A1MAPTHPGDCYP2C9 | |
| SCHEMBL2818009 | 0.87 | FDPS (0.77) | FDPSALDH1A1MAPTHPGDCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| WO-2011006000-A1 | BERBERINE DERIVATIVES USEFUL FOR MODULATING LIPID LEVELS AND THEIR METHODS OF SYNTHESIS | LIU HAIYAN (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010075469-A1 | CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | LIPC, LDLR, PCSK9 | FDPS 203/4885ALDH1A1 3512/4885MAPT 3477/4885 |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, LDLR, PCSK9 | FDPS 249/4885ALDH1A1 2335/4885MAPT 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.